• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION ELUVIA DRUG-ELUTING VASCULAR STENT SYSTEM; STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION ELUVIA DRUG-ELUTING VASCULAR STENT SYSTEM; STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING Back to Search Results
Model Number 24653
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Reocclusion (1985)
Event Date 11/28/2019
Event Type  Injury  
Event Description
It was reported that restenosis occurred.The subject was enrolled in the eminent study on (b)(6) 2017 and the index procedure was performed on the same day.Target lesion was located in left mid sfa with 100% stenosis and was 50 mm long with a proximal reference vessel diameter of 5 mm and distal reference vessel diameter of 5.3 mm and was classified as tasc ii a lesion.Target lesion was treated with pre-dilation followed by placement of a 7 mm x 60 mm study stent.Following post dilation, residual stenosis was 0%.On (b)(6) 2017, the subject was discharged with antiplatelet medications.On (b)(6) 2019, 710 days post index procedure, the subject presented to the enrolling site for the protocol specified 2-year follow-up visit.Rutherford category assessed on the same day was 0 (asymptomatic).Diagnostic tests revealed 70% stenosis of the femoral artery on the left -proximal to the stent.Intervention was planned on a later date.On (b)(6) 2019, the subject was hospitalized for the planned intervention.On (b)(6) 2019, 731 days post index procedure, the 70% stenosis in left proximal and distal sfa was treated with percutaneous transluminal angioplasty (pta) and stenting resulting in 0% final stenosis.On (b)(6) 2019, the event was resolved and the subject was discharged on (b)(6) 2019.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ELUVIA DRUG-ELUTING VASCULAR STENT SYSTEM
Type of Device
STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
two scimed place
maple grove MN 55311
Manufacturer (Section G)
BOSTON SCIENTIFIC CORPORATION
two scimed place
maple grove MN 55311
Manufacturer Contact
jay johnson
two scimed place
maple grove, MN 55311
7634942574
MDR Report Key10825284
MDR Text Key215895484
Report Number2134265-2020-15636
Device Sequence Number1
Product Code NIU
Combination Product (y/n)N
Reporter Country CodeAU
PMA/PMN Number
P180011
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Reporter Occupation Physician
Type of Report Initial
Report Date 11/11/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/11/2020
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date02/28/2018
Device Model Number24653
Device Catalogue Number24653
Device Lot Number0019719930
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received10/23/2020
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured08/17/2016
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
Patient Age59 YR
-
-